UK regulator approves 2nd Alzheimer's drug

LONDON, Oct 23 (AP): Britain's drug regulator approved the Alzheimer's drug Kisunla on Wednesday, but the government won't be paying for it after an independent watchdog agency said the treatment isn't worth the cost to taxpayers.
It is the second Alzheimer's drug to receive such a mixed reception within months. In August, the U.K. regulator authorized Leqembi while the same watchdog agency issued draft guidance recommending against its purchase for the National Health Service.
In a statement on Wednesday, Britain's Medicines and Healthcare regulatory Agency said Kisunla "showed some evidence of efficacy in slowing (Alzheimer's) progression" and approved its use to treat people in the early stages of the brain-robbing disease. Kisunla, also known as donanemab, works by removing a sticky protein from the brain believed to cause Alzheimer's disease.